Results 231 to 240 of about 148,079 (360)
Immunophenotypic characteristics of plasma cells in POEMS syndrome
Abstract To analyze the immunophenotypic characteristics of plasma cells in patients with polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes (POEMS) syndrome. This retrospective study included patients with POEMS syndrome hospitalized in the Department of Hematology, Huashan Hospital, from September 2017 to August 2025 ...
Zhenhua Wang +6 more
wiley +1 more source
The Expression of Matrix Metalloproteinases in Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-expressing Cancer of Apocrine Origin [PDF]
Yumi Kambayashi +8 more
openalex +1 more source
Fibroblast Plasticity in Inflammation of the Barrier
Under inflammatory condition, fibroblasts in barrier tissues integrate inflammatory, senescent, and mechanical inputs. These pathways activate central signaling networks to drive fibroblast phenotypic transition, enabling cytokine production, immune cell recruitment, and extracellular matrix remodeling.
Chen Zhang, Hao Wu, Wei Li
wiley +1 more source
Receptor activator of nuclear factor kappa‐B ligand (
Taku Fujimura +6 more
openalex +1 more source
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang +7 more
wiley +1 more source
Angiotensin II (AngII) activates nuclear factor-$kappa;B via AT1 and AT2 receptors in the kidney [PDF]
Marta Ruiz‐Ortega
openalex +1 more source
The multiple hit model of infantile and epileptic spasms: The 2025 update
Abstract Objective Infantile and epileptic spasms syndrome (IESS) is a developmental and epileptic encephalopathy manifesting with epileptic spasms and poor neurodevelopmental outcomes. There is an urgent need for the development of more effective and tolerated therapies.
Aristea S. Galanopoulou +6 more
wiley +1 more source

